Choosing Decentralized Clinical Trials
The Rise of DCTs
The COVID-19 pandemic has challenged the viability of traditional clinical trials around the world. The use of decentralized clinical trial (DCT) options was on the rise before the pandemic, but the industry’s growing need to keep research moving forward and ensure the safety of clinicians and patients made the need for remote capabilities more important than ever. With new efficiencies produced by telemedicine, remote monitoring, direct-to-patient shipments, devices, and more, these new options will remain an important attribute of clinical trials as we enter the digital age of research.
Why Choose DCTs
As the clinical landscape continues to evolve, DCTs present opportunities to emphasize convenience, safety, and flexibility, while continuing to pursue quality data and valuable research. Advantages include:
Building Decentralized Clinical Trials for Patients and Clinicians
The increased implementation of decentralized clinical trials means the industry now has a considerable body of evidence and experience to test the strengths of digital clinical trial models. With the growing amount of data comes the ability to assess how to make trials more effective and efficient, including a closer look at qualitative sponsor, site and patient feedback. To gain further insight into this transformation, PPD explored the experiences that key stakeholders have had when approaching decentralized clinical trials.
Digital Innovation & Implementation
How can PPD’s suite of digital capabilities and solutions help you reach more patients?